By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study on Biotechnology is now available. According to news reporting originating in Hangzhou, People's Republic of China, by NewsRx journalists, research stated, "Macrophages are the most plastic cells in the hematopoietic system and they exhibit great functional diversity. They have been extensively applied in anti-inflammatory, anti-fibrotic and anti-cancer therapies."
The news reporters obtained a quote from the research from Zhejiang University, "However, the application of macrophages is limited by the efficiency of their engineering. The macrophage mannose receptor (MMR, CD206), a C-type lectin receptor, is ubiquitously expressed on macrophages and has a high affinity for mannose oligosaccharides. In the present study, we developed a novel non-viral vehicle with specific affinity for MMR. Mannan was cationized with spermine at a grafted ratio of ?12% to deliver DNA and was characterized as a stable system for delivery. This spermine-mannan (SM)-based delivery system was evaluated as a biocompatible vehicle with superior transfection efficiency on murine macrophages, up to 28.5-fold higher than spermine-pullulan, 11.5-fold higher than polyethylenimine and 3.0-fold higher than Lipofectamine™ 2000. We confirmed that the SM-based delivery system for macrophages transfection was MMR-specific and we described the intracellular transport of the delivery system."
According to the news reporters, the research concluded: "To our knowledge, this is the first study using SM to demonstrate a mannose receptor-specific gene delivery system, thereby highlighting the potential of a novel specific non-viral delivery vehicle for macrophage engineering."
For more information on this research see: Macrophage mannose receptor-specific gene delivery vehicle for macrophage engineering. Acta Biomaterialia, 2014;10(5):1847-55. (Elsevier - www.elsevier.com; Acta Biomaterialia - www.elsevier.com/wps/product/cws_home/702994)
Our news correspondents report that additional information may be obtained by contacting G.X. Ruan, Zhejiang Province Key Laboratory of Anti-Cancer Research, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, Zhejiang, People's Republic of China. Additional authors for this research include Y.Z. Chen, X.L. Yao, A. Du, G.P. Tang, Y.Q. Shen, Y. Tabata and J.Q Gao (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Hangzhou, Immunology, Macrophages, Gene Therapy, Myeloid Cells, Bioengineering, Connective Tissue Cells, People's Republic of China, Mononuclear Phagocyte System.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC